{"id":"NCT00038467","sponsor":"Pfizer","briefTitle":"Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer","officialTitle":"Randomized Double-Blind Trial In Postmenopausal Women With Primary Breast Cancer Who Have Received Adjuvant Tamoxifen For 2-3 Years, Comparing Subsequent Adjuvant Exemestane Treatment With Further Tamoxifen","status":"COMPLETED","phase":"PHASE3","dates":{"start":"1998-02","primaryCompletion":"2003-06","completion":"2013-03","firstPosted":"2002-06-03","resultsPosted":"2014-04-10","lastUpdate":"2014-05-07"},"enrollment":4740,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Breast Neoplasms"],"interventions":[{"type":"DRUG","name":"Tamoxifen","otherNames":[]},{"type":"DRUG","name":"Exemestane","otherNames":[]}],"arms":[{"label":"B","type":"ACTIVE_COMPARATOR"},{"label":"A","type":"EXPERIMENTAL"}],"summary":"To compare the sequential administration of exemestane with administration of further tamoxifen until 5 years in postmenopausal women with operable breast cancer who have already received 2-3 years of adjuvant tamoxifen, in terms of disease-free survival (DFS), overall survival (OS), incidence of contralateral breast cancer and long-term tolerability.","primaryOutcome":{"measure":"Disease-Free Survival (DFS) at Month 36 Post-Randomization: Main Study","timeFrame":"Baseline up to Month 36","effectByArm":[{"arm":"Exemestane","deltaMin":0.9,"sd":null},{"arm":"Tamoxifen","deltaMin":0.86,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.00003"}]},"eligibility":{"minAge":"30 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":2},"locations":{"siteCount":377,"countries":["United States","Argentina","Australia","Belgium","Bosnia and Herzegovina","Bulgaria","Croatia","Czechia","Denmark","Egypt","Estonia","France","Germany","Greece","Hong Kong","Hungary","Ireland","Israel","Italy","Luxembourg","Malta","Netherlands","New Zealand","Norway","Peru","Poland","Portugal","Romania","Russia","Serbia","Slovakia","Slovenia","South Africa","Spain","Sweden","Switzerland","United Kingdom"]},"refs":{"pmids":[],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=96-OEXE-031&StudyName=Randomized%20Trial%20Of%20Exemestane%20Versus%20Continued%20Tamoxifen%20In%20Postmenopausal%20Women%20With%20Early%20Breast%20Cancer"]},"adverseEventsSummary":{"seriousAny":{"events":383,"n":2320},"commonTop":["Hot flushes NOS","Fatigue","Arthralgia","Headache","Sweating increased"]}}